Search

Displaying results 1501 - 1510 of 7479 in total
  1. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do … Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083].

  2. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.

    Products: Nu-propafenone
  3. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.

  4. Drug

    Cynodon dactylon pollen

    go.drugbank.com/drugs/DB10351
    Approved

    It can be cutaneously, intradermally and subcutaneously administered to initiate an immune response in case of an allergic reaction.

  5. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. … It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances

  6. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  7. Drug

    Bilastine

    go.drugbank.com/drugs/DB11591
    Approved

    Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

  8. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. Bentoquatam contains bentonite, a clay, and is only effective as lon...

  9. Drug

    Phenoxyethanol

    go.drugbank.com/drugs/DB11304
    ApprovedInvestigational

    It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621]. … Phenoxyethanol has been classified as an antimicrobial and preservative by Health Canada [L2623].

  10. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    It can be subcutaneously administered to initiate an immune response in case of an allergic reaction.